Your browser doesn't support javascript.
loading
Blood and urine multi-omics analysis of the impact of e-vaping, smoking, and cessation: from exposome to molecular responses.
Poussin, Carine; Titz, Bjoern; Xiang, Yang; Baglia, Laurel; Berg, Rachel; Bornand, David; Choukrallah, Mohammed-Amin; Curran, Timothy; Dijon, Sophie; Dossin, Eric; Dulize, Remi; Etter, Doris; Fatarova, Maria; Medlin, Loyse Felber; Haiduc, Adrian; Kishazi, Edina; Kolli, Aditya R; Kondylis, Athanasios; Kottelat, Emmanuel; Laszlo, Csaba; Lavrynenko, Oksana; Eb-Levadoux, Yvan; Nury, Catherine; Peric, Dariusz; Rizza, Melissa; Schneider, Thomas; Guedj, Emmanuel; Calvino, Florian; Sierro, Nicolas; Guy, Philippe; Ivanov, Nikolai V; Picavet, Patrick; Spinelli, Sherry; Hoeng, Julia; Peitsch, Manuel C.
Afiliação
  • Poussin C; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Titz B; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Xiang Y; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland. yang.xiang@pmi.com.
  • Baglia L; University of Rochester Medical Center, Rochester, NY, USA.
  • Berg R; University of Rochester Medical Center, Rochester, NY, USA.
  • Bornand D; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Choukrallah MA; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Curran T; University of Rochester Medical Center, Rochester, NY, USA.
  • Dijon S; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Dossin E; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Dulize R; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Etter D; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Fatarova M; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Medlin LF; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Haiduc A; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Kishazi E; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Kolli AR; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Kondylis A; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Kottelat E; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Laszlo C; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Lavrynenko O; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Eb-Levadoux Y; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Nury C; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Peric D; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Rizza M; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Schneider T; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Guedj E; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Calvino F; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Sierro N; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Guy P; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland. philippalexandre.guy@pmi.com.
  • Ivanov NV; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland. nikolai.ivanov@unine.ch.
  • Picavet P; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Spinelli S; University of Rochester Medical Center, Rochester, NY, USA.
  • Hoeng J; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
  • Peitsch MC; PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
Sci Rep ; 14(1): 4286, 2024 02 21.
Article em En | MEDLINE | ID: mdl-38383592
ABSTRACT
Cigarette smoking is a major preventable cause of morbidity and mortality. While quitting smoking is the best option, switching from cigarettes to non-combustible alternatives (NCAs) such as e-vapor products is a viable harm reduction approach for smokers who would otherwise continue to smoke. A key challenge for the clinical assessment of NCAs is that self-reported product use can be unreliable, compromising the proper evaluation of their risk reduction potential. In this cross-sectional study of 205 healthy volunteers, we combined comprehensive exposure characterization with in-depth multi-omics profiling to compare effects across four study groups cigarette smokers (CS), e-vapor users (EV), former smokers (FS), and never smokers (NS). Multi-omics analyses included metabolomics, transcriptomics, DNA methylomics, proteomics, and lipidomics. Comparison of the molecular effects between CS and NS recapitulated several previous observations, such as increased inflammatory markers in CS. Generally, FS and EV demonstrated intermediate molecular effects between the NS and CS groups. Stratification of the FS and EV by combustion exposure markers suggested that this position on the spectrum between CS and NS was partially driven by non-compliance/dual use. Overall, this study highlights the importance of in-depth exposure characterization before biological effect characterization for any NCA assessment study.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Abandono do Hábito de Fumar / Produtos do Tabaco / Sistemas Eletrônicos de Liberação de Nicotina / Vaping / Expossoma Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Abandono do Hábito de Fumar / Produtos do Tabaco / Sistemas Eletrônicos de Liberação de Nicotina / Vaping / Expossoma Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça